Marker Therapeutics (NASDAQ:MRKR) Now Covered by Analysts at Canaccord Genuity Group

Canaccord Genuity Group assumed coverage on shares of Marker Therapeutics (NASDAQ:MRKR) in a research note released on Wednesday, MarketBeat.com reports. The firm issued a buy rating and a $8.00 target price on the stock.

Separately, Brookline Capital Management upgraded Marker Therapeutics to a “strong-buy” rating in a research report on Monday, February 10th.

Marker Therapeutics Stock Performance

Shares of MRKR stock opened at $1.84 on Wednesday. Marker Therapeutics has a 52-week low of $1.35 and a 52-week high of $5.99. The stock’s 50-day moving average price is $2.22 and its 200 day moving average price is $2.99.

Insiders Place Their Bets

In other Marker Therapeutics news, major shareholder Enterprise Associates 16 New bought 554,250 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were bought at an average price of $3.20 per share, for a total transaction of $1,773,600.00. Following the transaction, the insider now owns 1,625,678 shares of the company’s stock, valued at approximately $5,202,169.60. This trade represents a 51.73 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Steve Elms bought 11,085 shares of the company’s stock in a transaction on Monday, December 23rd. The shares were acquired at an average price of $3.20 per share, for a total transaction of $35,472.00. Following the transaction, the director now directly owns 325,370 shares in the company, valued at $1,041,184. This trade represents a 3.53 % increase in their position. The disclosure for this purchase can be found here. 14.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Marker Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in MRKR. Invst LLC purchased a new stake in shares of Marker Therapeutics during the 3rd quarter worth approximately $56,000. Millennium Management LLC purchased a new stake in shares of Marker Therapeutics during the 4th quarter worth approximately $50,000. Northern Trust Corp boosted its stake in shares of Marker Therapeutics by 66.9% during the 4th quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock worth $168,000 after acquiring an additional 21,703 shares in the last quarter. NEA Management Company LLC boosted its stake in shares of Marker Therapeutics by 51.7% during the 4th quarter. NEA Management Company LLC now owns 1,625,678 shares of the company’s stock worth $5,056,000 after acquiring an additional 554,250 shares in the last quarter. Finally, Alyeska Investment Group L.P. purchased a new stake in shares of Marker Therapeutics during the 4th quarter worth approximately $2,847,000. Institutional investors and hedge funds own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.